Form 4: Vericel Corp Director Heidi Hagen Exercises Stock Options
SEC Form 4 Filing
Director Heidi Hagen exercised stock options to acquire 10,000 shares of Vericel Corp common stock at a price of $3.74 per share on October 17, 2024.
Summary
- On October 17, 2024, Heidi Hagen, a director of Vericel Corp, exercised stock options.
- She acquired 4,000 shares at a price of $3.74 per share and holds 22,650 shares directly.
- She acquired 6,000 shares at a price of $3.74 per share and holds 28,650 shares directly.
- The options were granted on March 20, 2015, and were set to expire on March 20, 2025.
- The options vested in installments based on continued service to the company.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction disclosure.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine exercise of stock options.
Key Dates
| Date | Description |
|---|---|
| March 20, 2015 | Date the stock options were granted. |
| May 1, 2015 | Final vesting date for some of the options. |
| March 20, 2025 | Original expiration date of the options. |
| October 17, 2024 | Date of the stock option exercise. |
| October 21, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.